Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) EPS (Weighted Average and Diluted) (2016 - 2025)

Aptevo Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at $19.42 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 105.43% year-over-year to $19.42; the TTM value through Sep 2025 reached -$369.28, up 81.2%, while the annual FY2023 figure was $164.87, 10401.29% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was $19.42 at Aptevo Therapeutics, up from -$26.45 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $38.99 in Q4 2023 and bottomed at -$1237.0 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.25 (2021), against an average of -$128.98.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 16341.81% in 2023 before it crashed 6311.97% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.25 in 2021, then increased by 19.2% to -$1.01 in 2022, then soared by 3960.27% to $38.99 in 2023, then crashed by 1017.86% to -$357.86 in 2024, then surged by 105.43% to $19.42 in 2025.
  • Per Business Quant, the three most recent readings for APVO's EPS (Weighted Average and Diluted) are $19.42 (Q3 2025), -$26.45 (Q2 2025), and -$4.39 (Q1 2025).